BBIO
BridgeBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive pivotal readouts and favorable regulatory/partnering outcomes trigger re-rating toward analyst highs.
Posture
Mixed
Lead driver
Sentiment
What changed
1 setup hits (3d) with net bearish as of 2026-06-03.
What can break
Clinical failure or missed endpoints for key programs
Momentum
27
Value
41
Sentiment
79
Setup hits (3d)
1 · Net Bearish
AI TargetsBase $85.79 · Bull $115.50 · Bear $42.63
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-19 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bearish
Target $100.10
Why
Momentum27 · Δ7d +1.8
Value41 · Δ7d +0.1
Sentiment79 · Δ7d +10.6
So what
Balanced signals (Net Bearish). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
27
34% active weight
Current posture
7d trendFlat
Δ7d
+1.8
Δ21d
+6.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
79
33% active weight
Current posture
7d trendImproving
Δ7d
+10.6
Δ21d
+8.0
Why this grade
Composite grade C. Momentum 26.9 / Value 41.1 / Sentiment 79.4
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$12.8B
Beta
1.13
Shares Out
192.71M
P/E (TTM) · Derived
-17.6
P/S (TTM)
39.99
P/FCF (TTM) · Derived
-21.17
Rev YoY
+4318.0%
EPS YoY
-10.8%
Gross Margin
+95.8%
Op Margin
-178.4%
Net Debt
$1.52B
Current Ratio
3.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology